0000950123-11-047645.txt : 20110510
0000950123-11-047645.hdr.sgml : 20110510
20110509194419
ACCESSION NUMBER: 0000950123-11-047645
CONFORMED SUBMISSION TYPE: SC 13D/A
PUBLIC DOCUMENT COUNT: 3
FILED AS OF DATE: 20110510
DATE AS OF CHANGE: 20110509
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: METLIFE INC
CENTRAL INDEX KEY: 0001099219
STANDARD INDUSTRIAL CLASSIFICATION: LIFE INSURANCE [6311]
IRS NUMBER: 134075851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13D/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-58857
FILM NUMBER: 11825349
BUSINESS ADDRESS:
STREET 1: 1095 AVENUE OF AMERICAS
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 212-578-5500
MAIL ADDRESS:
STREET 1: 1095 AVENUE OF AMERICAS
CITY: NEW YORK
STATE: NY
ZIP: 10036
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: BOARD OF DIRECTORS OF METLIFE INC
CENTRAL INDEX KEY: 0001111726
IRS NUMBER: 000000000
FILING VALUES:
FORM TYPE: SC 13D/A
BUSINESS ADDRESS:
STREET 1: ONE MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10010-3690
BUSINESS PHONE: 2125782211
MAIL ADDRESS:
STREET 1: ONE MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10010-3690
SC 13D/A
1
y91121sc13dza.txt
SC 13D/A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 45 TO
SCHEDULE 13D
Under the Securities Exchange Act of 1934
MetLife, Inc.
(Name of Issuer)
Common Stock, par value $.01 per share
(Title of Class of Securities)
59156R108
(CUSIP Number)
Nicholas D. Latrenta
Executive Vice President and General Counsel
MetLife, Inc.
200 Park Avenue
New York, NY 10166-0188
(212) 578-2211
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
May 9, 2011
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 10 Pages
Page 2 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
--------------------------------------------------------------------------------
(1) Names of Reporting Persons Board of Directors of MetLife, Inc.,
as an entity
I.R.S. Identification
Nos. of Above Persons Not applicable
--------------------------------------------------------------------------------
(2) Check the Appropriate Box if (a) [ ]
a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
(3) SEC Use Only
--------------------------------------------------------------------------------
(4) Source of Funds Not Applicable. See Item 4
--------------------------------------------------------------------------------
(5) Check if Disclosure of Legal
Proceedings is Required
Pursuant to Items 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
(6) Citizenship or Place of
Organization U.S.A.
--------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power 0
Beneficially Owned
by Each Reporting ---------------------------------------------------------
Person With
(8) Shared Voting Power 217,992,713*
---------------------------------------------------------
(9) Sole Dispositive Power 0
---------------------------------------------------------
(10) Shared Dispositive Power 0
--------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially
Owned by Each Reporting Person 217,992,713
--------------------------------------------------------------------------------
(12) Check if the Aggregate Amount
in Row (11) Excludes Certain
Shares [ ]
--------------------------------------------------------------------------------
(13) Percent of Class Represented
by Amount in Row 11 20.6%
--------------------------------------------------------------------------------
(14) Type of Reporting Person OO
--------------------------------------------------------------------------------
* Unless otherwise indicated, all information relating to beneficial ownership
of the Shares by the Reporting Persons is as of May 2, 2011.
Page 3 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
Items 4 and 5 are amended and restated as set forth below:
ITEM 4. PURPOSE OF TRANSACTION.
The Board of Directors is reporting beneficial ownership of
217,992,713 shares of Common Stock (the "Shares") held by the MetLife
Policyholder Trust (the "Trust") under the Plan of Reorganization, dated
September 28, 1999, as amended (the "Plan"), of Metropolitan Life Insurance
Company ("MetLife").
On April 7, 2000, 494,466,664 Shares were issued to the Trust
pursuant to Section 5.2(d) of the Plan, a copy of which is attached as an
exhibit to this statement. No consideration has been separately provided
therefor by any member of the Board of Directors, except for Shares allocated to
such member pursuant to the Plan. Since April 7, 2000, transactions by
Beneficiaries (i) under the Purchase and Sale Program provided for by the Trust
Agreement (as defined below), (ii) pursuant to the Issuer's split-off of
Reinsurance Group of America, Incorporated, in September 2008, and (iii) to
withdraw Shares from the Trust, as well as escheatment of unclaimed Shares, have
resulted in a decrease in the number of Shares held by the Trust from
494,466,664 to 217,992,713 (as adjusted to reflect refinements in the
calculation of the number of Shares issued to the Trust under the Plan).
Under the Plan and the MetLife Policyholder Trust Agreement, dated
as of November 3, 1999 (as amended, the "Trust Agreement"), by and among
MetLife, the Issuer, Wilmington Trust Company (the "Trustee") and ChaseMellon
Shareholder Services, L.L.C., as custodian (now known as Mellon Investor
Services LLC, the "Custodian"), a copy of which is attached as an exhibit to
this statement, certain eligible policyholders of MetLife ("Trust Eligible
Policyholders") have been allocated a number of interests in the Trust ("Trust
Interests") equal to the number of shares of Common Stock allocated to the Trust
Eligible Policyholders in accordance with the Plan. The assets of the Trust
principally are the Shares issued to the Trust for the benefit of the Trust
Eligible Policyholders and permitted transferees (collectively, the
"Beneficiaries"). The Shares are held in the name of the Trustee, on behalf of
the Trust, which has legal title over the Shares. The Beneficiaries do not have
legal title to any part of the assets of the Trust. The Trust Interests
represent undivided fractional interests in the Shares and other assets of the
Trust beneficially owned by a Trust Beneficiary through the Custodian.
The Trust Agreement provides the Trustee with directions as to the
manner in which to vote, assent or consent the Shares at all times during the
term of the Trust. On all matters brought for a vote before the stockholders of
the Issuer, with the exception of a Beneficiary Consent Matter (as defined
below), the Trustee will vote in accordance with the recommendation given by the
Board of Directors of the Issuer to its stockholders or, if no such
recommendation is given, as directed by the Board. On all Beneficiary Consent
Matters, the Trustee will vote all of the Shares in favor of, in opposition to
or abstain from the matter in the same ratio as the Trust Interests of the
Beneficiaries that returned voting instructions to the Trustee indicated
preferences for voting in favor of, in opposition to or abstaining from such
matter. The Trust Agreement also contains provisions allowing Beneficiaries to
instruct the Custodian to withdraw their allocated Trust Shares to participate
in any tender or exchange offer for the Common Stock and to make any cash or
share election, or perfect any dissenter's rights, in connection with a merger
of the Issuer.
Page 4 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
A "Beneficiary Consent Matter" is:
(i) a contested election of directors or, subject to certain conditions,
the removal of a director,
(ii) a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets or a recapitalization or dissolution
of the Issuer, if it requires a vote of stockholders under
applicable Delaware law,
(iii) any transaction that would result in an exchange or conversion of
the Shares for cash, securities or other property,
(iv) issuances of Common Stock prior to the first anniversary of the
effective date of the Plan (the "Effective Date") at a price
materially below the prevailing market price, if a vote is required
to approve the issuance under Delaware law, other than issuances in
an underwritten public offering or pursuant to an employee benefit
plan,
(v) before the first anniversary of the Effective Date, any matter that
requires approval by a vote of more than a majority of the
outstanding stock of the Issuer entitled to vote thereon under
Delaware law or the certificate of incorporation or the by-laws of
the Issuer, and any amendment to the certificate of incorporation or
by-laws of the Issuer that is submitted to a vote of stockholders
for approval, and
(vi) proposals submitted to stockholders requiring the Board of Directors
to amend the Issuer's stockholder rights plan, or redeem rights
under that plan, other than a proposal with respect to which the
Issuer has received advice of nationally-recognized legal counsel to
the effect that the proposal is not a proper subject for stockholder
action under Delaware law. The Issuer does not currently have a
stockholder rights plan.
The Trust Agreement contains provisions enabling the
Beneficiaries to withdraw the Shares allocated to them under the Plan and the
Trust Agreement for resale or otherwise and to receive dividends on such Shares.
Page 5 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) As an entity, the Board of Directors of the Issuer beneficially owns
217,992,713 shares or 20.6% of the Issuer's outstanding Common Stock.
The Board of Directors of the Issuer is deemed to beneficially own the
shares of Common Stock held by the Trust because the Board will direct the
voting of these shares on certain matters submitted to a vote of
stockholders. See Item 4.
(b) As an entity, the Board of Directors of the Issuer has shared voting power
with respect to 217,992,713 shares of Common Stock.
(c) There were no transactions in the class of securities reported on that
were effected by the Reporting Persons since February 18, 2011, other than
transactions described in Item 4 which resulted in a decrease in the
number of shares of Common Stock held by the Trust from 220,255,199 to
217,992,713.
(d) The Beneficiaries of the Trust have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of,
the Shares allocated to them under the Plan and the Trust Agreement. See
Item 4.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit 99.1 Joint Filing Agreement under Rule 13d-1(k)(1)
Exhibit 99.2 Power of Attorney
Page 6 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
SIGNATURES.
After reasonable inquiry and to the best of my knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct.
Dated: May 9, 2011
*
----------------------------
C. Robert Henrikson
*
----------------------------
Sylvia Mathews Burwell
*
----------------------------
Eduardo Castro-Wright
*
----------------------------
Cheryl W. Grise
*
----------------------------
R. Glenn Hubbard
*
----------------------------
Steven A. Kandarian
*
----------------------------
John M. Keane
*
----------------------------
Alfred F. Kelly, Jr.
*
----------------------------
James M. Kilts
*
----------------------------
Catherine R. Kinney
Page 7 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
*
----------------------------
Hugh B. Price
*
----------------------------
David Satcher, M.D.
*
----------------------------
Kenton J. Sicchitano
*
----------------------------
Lulu C. Wang
* By /s/ Nicholas D. Latrenta
-------------------------
Nicholas D. Latrenta
Attorney-in-fact
Page 8 of 10 Pages
Exhibit Index
-------------
99.1 Joint Filing Agreement under Rule 13d-1(K)(l)
99.2 Power of Attorney
EX-99.1
2
y91121exv99w1.txt
EX-99.1
Exhibit 99.1
Page 9 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
JOINT FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange
Act of 1934, as amended, each of the undersigned agrees that the Statement on
Amendment No. 45 to Schedule 13D, to which this exhibit is attached, is filed
on his or her behalf.
Dated: May 9, 2011
*
----------------------------
C. Robert Henrikson
*
----------------------------
Sylvia Mathews Burwell
*
----------------------------
Eduardo Castro-Wright
*
----------------------------
Cheryl W. Grise
*
----------------------------
R. Glenn Hubbard
*
----------------------------
Steven A. Kandarian
*
----------------------------
John M. Keane
*
----------------------------
Alfred F. Kelly, Jr.
*
----------------------------
James M. Kilts
*
----------------------------
Catherine R. Kinney
Page 10 of 10 Pages
SCHEDULE 13D
CUSIP No. 59156R108
*
----------------------------
Hugh B. Price
*
----------------------------
David Satcher, M.D.
*
----------------------------
Kenton J. Sicchitano
*
----------------------------
Lulu C. Wang
* By /s/ Nicholas D. Latrenta
------------------------
Nicholas D. Latrenta
Attorney-in-fact
EX-99.2
3
y91121exv99w2.txt
EX-99.2
Exhibit 99.2
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes
and appoints Nicholas D. Latrenta, Executive Vice President and General Counsel,
William J. Wheeler, Executive Vice President and Chief Financial Officer, and
Steven J. Goulart, Senior Vice President and Treasurer, or any of them, and
their respective successors from time to time in the offices of General Counsel,
Chief Financial Officer, or Treasurer, as the case may be, as such person's true
and lawful attorney-in-fact and agent for such person and in such person's name,
place and stead, in any and all capacities, to sign individually and not
collectively, (i) any and all amendments to a Schedule 13D with regard to the
MetLife, Inc. Board of Directors' beneficial ownership of securities of MetLife,
Inc. ("Schedule 13D"), and to file the same, with exhibits thereto and other
documents related thereto, with the Securities and Exchange Commission, and
(ii) any and all other instruments which any of such attorneys-in-fact and
agents deems necessary or advisable to comply with all applicable laws, rules
and regulations in connection with the matters authorized by clause (i), and
does hereby grant unto each such attorney-in-fact and agent full power and
authority to do and perform each and every act and thing requisite and necessary
to be done in and about the premises, as fully to all intents and purposes as
such person might or could do in person, hereby ratifying and confirming all
that each said attorney-in-fact and agent may lawfully do or cause to be done by
virtue hereof. The authority of Nicholas D. Latrenta, Executive Vice President
and General Counsel, William J. Wheeler, Executive Vice President and Chief
Financial Officer, and Steven J. Goulart, Senior Vice President and Treasurer,
or any of their respective successors from time to time in the offices of
General Counsel, Chief Financial Officer, or Treasurer, as the case may be,
under this Power of Attorney shall continue until the Board of Directors is no
longer required to file amendments to the Schedule 13D, except that such
authority shall be terminated with respect to such person whose signature
appears below when such person revokes in writing the authority granted hereby.
This Power of Attorney does not revoke any prior powers of attorney.
Dated: April 28, 2011
/s/ Steven A. Kandarian
------------------------
Steven A. Kandarian